PD-L1 Up-Regulation in Prostate Cancer Cells by Porphyromonas gingivalis

被引:18
|
作者
Groeger, Sabine [1 ,2 ]
Wu, Fan [1 ]
Wagenlehner, Florian [3 ]
Dansranjav, Temuujin [3 ]
Ruf, Sabine [2 ]
Denter, Fabian [1 ]
Meyle, Joerg [1 ]
机构
[1] Justus Liebig Univ, Dept Periodontol, Giessen, Germany
[2] Justus Liebig Univ, Dept Orthodont, Giessen, Germany
[3] Justus Liebig Univ, Clin Urol, Giessen, Germany
来源
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY | 2022年 / 12卷
关键词
periodontitis; prostate cancer; Porphyromonas gingivalis; PD-L1; up-regulation; immune evasion; INFLAMMATION; INFECTION; IMMUNITY; PATHOGEN; NOD1;
D O I
10.3389/fcimb.2022.935806
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Chronic inflammation is known to contribute to various human cancers. Porphyromonas gingivalis (P. gingivalis), is a gram-negative oral keystone pathogen that may cause severe periodontitis and expresses several virulence factors to affect the host immune system. Periodontitis is a chronic infectious disease that while progression, may cause loss of attachment and destruction of the tooth supporting tissues. Prostate cancer is one of the most common malignancies in men. Increasing evidence links periodontitis with prostate cancer, however the mechanisms explaining this relationship remain unclear. The aim of this study was to investigate the expression and signaling pathway of programmed death ligand 1 (PD-L1) in a prostate cancer cell line after infection with P. gingivalis and stimulation with P. gingivalis components to reveal the mechanism of tumor-induced immune evasion associated with bacterial infection in the tumor environment. Prostate cancer cells were infected with different concentrations of viable P. gingivalis and treated with different concentrations of heat-killed P. gingivalis and P. gingivalis cell components, including the total membrane fraction, inner membrane fraction, outer membrane fraction, cytosolic fraction and peptidoglycan (PGN). Chemical inhibitors were used to block different important molecules of signaling pathways to assess the participating signal transduction mechanisms. PD-L1 expression was detected by Western blot after 24 h of infection. PD-L1 was demonstrated to be upregulated in prostate cancer cells after infection with viable and with heat-killed P. gingivalis membrane fractions. Also isolated PGN induced PD-L1 up-regulation. The upregulation was mediated by the NOD1/NOD2 signaling pathway. No upregulation could be detected after treatment of the cells with P. gingivalis lipopolysaccharide (LPS). These results indicate, that chronic inflammatory disease can contribute to tumor immune evasion by modifying the tumor microenvironment. Thus, chronic infection possibly plays an essential role in the immune response and may promote the development and progression of prostate cancer.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] The up-regulation of PD-L1 during boningmycin-induced senescence in human cancer cells depends on the activation of the JAK/STAT signaling pathway mediated by SASP
    Chen, Yang
    Shen, Jiajia
    Zhao, Xiaoli
    He, Qiyang
    Zhang, Juan
    IMMUNOLOGY AND CELL BIOLOGY, 2024, 102 (09): : 847 - 859
  • [42] PD-L1: expression regulation
    Zhou, Yu-Jie
    Li, Guoli
    Wang, Jiyin
    Liu, Mengyuan
    Wang, Zihan
    Song, Yu
    Zhang, Xulong
    Wang, Xi
    BLOOD SCIENCE, 2023, 5 (02): : 77 - 91
  • [43] MUC1-C Inhibition Leads to Decrease in PD-L1 Levels Via up-Regulation of Micro RNAs
    Pyzer, Athalia Rachel
    Stroopinsky, Dina
    Rosenblatt, Jacalyn
    Anastasiadou, Eleni
    Rajabi, Hasan
    Washington, Abigail J.
    Tagde, Ashujit
    Coll, Maxwell Douglas
    Cole, Leandra
    Palmer, Kristen Anna
    Somaiya, Poorvi
    Leaf, Rebecca Karp
    Nahas, Myrna R.
    Apel, Arie
    Jain, Salvia
    Joyce, Robin
    Arnason, Jon
    Slack, Frank
    Kufe, Donald
    Avigan, David E.
    BLOOD, 2016, 128 (22)
  • [44] Up-Regulation of Donor Dendritic Cell PD-L1 Expression Reduced Recipient Lymphocyte Activation and Proliferation In Vitro
    Li, Tao
    Ma, Rui
    Zhu, Ji-Ye
    TRANSPLANTATION PROCEEDINGS, 2021, 53 (02) : 716 - 723
  • [45] Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
    Bai, Jie
    Gao, Zhitao
    Li, Xiang
    Dong, Liang
    Han, Weidong
    Nie, Jing
    ONCOTARGET, 2017, 8 (66) : 110693 - 110707
  • [46] Immunohistochemistry of Immune Checkpoint Markers PD-1 and PD-L1 in Prostate Cancer
    Sharma, Meenal
    Yang, Qi
    Mcmahon, Loralee
    Miyamoto, Hiroshi
    MODERN PATHOLOGY, 2019, 32
  • [47] Immunohistochemistry of Immune Checkpoint Markers PD-1 and PD-L1 in Prostate Cancer
    Sharma, Meenal
    Yang, Qi
    Mcmahon, Loralee
    Miyamoto, Hiroshi
    LABORATORY INVESTIGATION, 2019, 99
  • [48] Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer
    Sharma, Meenal
    Yang, Zhiming
    Miyamoto, Hiroshi
    MEDICINE, 2019, 98 (38)
  • [49] PD-L1 overexpression in prostate cancer: a potential targeted therapy
    Aditya, Gede Andi
    Dany, Yurisal Akhmad
    Danarto, Raden
    Soeroharjo, Indrawarman
    Hendri, Ahmad Zulfan
    BALI MEDICAL JOURNAL, 2023, 12 (02) : 2303 - 2306
  • [50] PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
    Bishop, Jennifer L.
    Sio, Alexander
    Angeles, Arkhjamil
    Roberts, Morgan E.
    Azad, Arun A.
    Chi, Kim N.
    Zoubeidi, Amina
    ONCOTARGET, 2015, 6 (01) : 234 - 242